Boston Scientific's shares ($BSX) experienced a significant 9% drop midday following reports of problems with the company's pacemaker batteries. Further weighing on the stock, WATCHMAN data revealed a nuance of higher-than-expected stroke risk, despite also supporting long-term adoption by meeting primary endpoints and demonstrating a 45% reduction in bleeding compared to NOACs. Analysts recommended selling on the news in the near term, though the data still indicated long-term adoption potential. Amid these developments, Boston Scientific also received positive news with FDA clearance for its Asurys™ Fluid Management System.
Boston Scientific's stock saw a notable drop due to pacemaker battery issues and mixed WATCHMAN data, which revealed higher stroke risk but also supported long-term adoption. Analysts advised selling in the near-term, while the company also received positive FDA clearance for a new system.
Agreed-upon facts
Boston Scientific's Immediate Stock Reaction and Key News
Where narratives collide
No material split surfaced for this cluster—sources align on the core read.
Where sources say this may head next
Near-term Trading Recommendation and Long-term Product Adoption Outlook